Immunogen Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Date: October 15, 2016
Pages: 50
US$ 499.00
Immunogen Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)
ID: I704B0E0886BEN

Download PDF Leaflet

Immunogen Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Immunogen Inc. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Immunogen Inc. and its competitors. This provides our Clients with a clear understanding of Immunogen Inc. position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about Immunogen Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for Immunogen Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The Immunogen Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes Immunogen Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Immunogen Inc. business.

About Immunogen Inc.

ImmunoGen, Inc. focuses on the development of antibody-based anticancer therapeutics.

Product Candidates

Trastuzumab-DM1 (T-DM1): T-DM1 consists of the company’s DM1 cell-killing agent attached to trastuzumab, which is the active component of the marketed anticancer compound, Herceptin.

In July 2010, Roche announced the submission of a biologics license application (BLA), to the Food Drug Administration (FDA) to gain U.S. marketing approval for use of T-DM1 to treat patients with HER2+ breast cancer who had previously received multiple chemotherapies and HER2-targeted medicines; this is also known as 3rd-line use.

Lorvotuzumab mertansine

The company’s wholly owned compound is lorvotuzumab mertansine, also known as IMGN901. The target for this targeted antibody payload (TAP) compound, CD56, is found on various tumor types, including small-cell lung cancer, ovarian cancer, Merkel cell carcinoma, and the liquid tumor, multiple myeloma.

The company is evaluating lorvotuzumab mertansine for the treatment of CD56+ cancers, focusing initially on small-cell lung cancer, Merkel cell carcinoma, ovarian cancer, and multiple myeloma.


The company created this TAP compound for the treatment of non-Hodgkin's lymphoma and other B-cell malignancies and licensed it to sanofi-aventis as part of research collaboration. SAR3419 is in Phase I testing for the treatment of non-Hodgkin's lymphoma. Sanofi-aventis is evaluating the compound using a different dosing schedule in a second Phase I trial.


The company is developing IMGN388 for the treatment of solid tumors. It includes an integrin-targeting antibody developed by Centocor Ortho Biotech. IMGN388 is in Phase I testing. Centocor Ortho Biotech has opt-in rights for this compound.

Other Compounds in Development by the company

In addition to lorvotuzumab mertansine and IMGN388, the company has various product candidates at earlier stages in its pipeline. IMGN529 is a potential treatment for certain types of liquid tumors.

Other Compounds in Development by its Partners

In addition to T-DM1 and SAR3419, other compounds in clinical testing through its collaborations with other companies are BT-062, BIIB015, and SAR650984. Companies with licenses to develop TAP compounds in the clinic include Amgen, Bayer Schering Pharma, Genentech, and sanofi-aventis.

Genentech (a member of the Roche Group): The company has two separate agreements with Genentech. The first agreement grants Genentech a license to its maytansinoid TAP technology for use with antibodies that target HER2, such as trastuzumab. Under the terms of this agreement, Genentech has worldwide rights to develop and commercialize maytansinoid TAP compounds with antibodies that target HER2. Genentech is responsible for the manufacturing, product development and marketing of any products resulting from the agreement. Genentech and Roche began Phase III evaluation of T-DM1 in 2009.

The company also has a ‘right-to-test’ agreement with Genentech. This agreement provided Genentech with the right to test its maytansinoid TAP technology with antibodies to a defined number of targets for specified option periods and to take licenses to use its maytansinoid TAP technology to develop products directed to individual targets on agreed-upon terms.

Amgen: The company has an agreement with Amgen. The agreement provides Amgen with the right to test its maytansinoid TAP technology with antibodies to a defined number of targets for specified option periods and to take licenses to use its maytansinoid TAP technology to develop products for individual targets on agreed-upon terms.

sanofi-aventis: The company has a collaboration agreement with sanofi-aventis to discover, develop, and commercialize antibody-based anticancer therapeutics.

Biogen Idec: The company has a development and license agreement with Biogen Idec. The agreement grants Biogen Idec rights to use its maytansinoid TAP technology to develop and commercialize therapeutic compounds to the target Cripto. Biogen Idec is responsible for the research, development, manufacturing, and marketing of any products resulting from the license.

Biotest: The company has a license agreement with Biotest. The agreement grants Biotest rights to use its maytansinoid TAP technology to develop and commercialize therapeutic compounds directed to the target CD138.

Bayer Schering Pharma: The company has a development and license agreement with Bayer Schering Pharma AG. The agreement grants Bayer Schering Pharma rights to use its maytansinoid TAP technology to develop and commercialize therapeutic compounds directed to a specific target. Bayer Schering Pharma is responsible for the research, development, manufacturing and marketing of any products resulting from the license.

Significant Events

In December 2010, the government of Russia's St Petersburg region had entered a memorandum of understanding (MoU) with four pharmaceutical companies for the development of the planned pharmaceutical cluster, reports the Pharmvestnik news portal. The companies in question include Novartis AG, Pharmsynthez Open Joint Stock Company, Vertex, and ImmunoGen.


ImmunoGen, Inc. was founded in 1981.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.




1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History


2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units


3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats


4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot


5.1. Immunogen Inc. Direct Competitors
5.2. Comparison of Immunogen Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Immunogen Inc. and Direct Competitors Stock Charts
5.4. Immunogen Inc. Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Immunogen Inc. Industry Position Analysis


6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events


7.1. Experts Opinion
7.2. Experts Estimates



9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors


10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix





Immunogen Inc. Key Facts
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Immunogen Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Immunogen Inc. Major Shareholders
Immunogen Inc. History
Immunogen Inc. Products
Revenues by Segment
Revenues by Region
Immunogen Inc. Offices and Representations
Immunogen Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Immunogen Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Immunogen Inc. Capital Market Snapshot
Immunogen Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Immunogen Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Immunogen Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1


Immunogen Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Immunogen Inc. 1-year Stock Charts
Immunogen Inc. 5-year Stock Charts
Immunogen Inc. vs. Main Indexes 1-year Stock Chart
Immunogen Inc. vs. Direct Competitors 1-year Stock Charts
Immunogen Inc. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?
Skip to top

Ask Your Question

Immunogen Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: